Pfizer Completes Anacor Acquisition

(c) Pfizer
(c) Pfizer

Major drugmaker Pfizer has completed its $5.2 billion acquisition of Anacor Pharmaceuticals. The California, US-based company became a wholly-owned subsidiary of Pfizer on Jun. 24. “Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need,” said Albert Bourla, group president of Pfizer Innovative Health.

He added that Pfizer was now in a position to quickly capitalize on the benefits of combining with Anacor, including the potential for a near-term product launch in the US and subsequent commercialization of crisaborole, a treatment for atopic dermatitis. The drug is currently under review by the Food and Drug Administration (FDA) with approval anticipated next January.

Pfizer said the transaction was expected to be accretive to earnings from 2018 onward.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.